Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Abstract Background Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience immune-related adverse events (irAEs), which can...

Полное описание

Библиографические подробности

Главные авторы:	Michael F. Gowen, Keith M. Giles, Danny Simpson, Jeremy Tchack, Hua Zhou, Una Moran, Zarmeena Dawood, Anna C. Pavlick, Shaohui Hu, Melissa A. Wilson, Hua Zhong, Michelle Krogsgaard, Tomas Kirchhoff, Iman Osman
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2018-04-01
Серии:	Journal of Translational Medicine
Предметы:	Melanoma Immunotherapy Antibodies Toxicity Biomarker
Online-ссылка:	http://link.springer.com/article/10.1186/s12967-018-1452-4
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!